Company Aggregate Debt: veracyte.com (VCYT)

Veracyte, Inc. (VCYT) is advancing genomic diagnostics by increasing sales of Afirma and Decipher tests through AI technologies. Stable management is effectively expanding the high-margin product line, earning the market's trust. Demand for oncology analysis remains independent of economic conditions, confirming the business's macro-resilience. The debt capital volume on this chart demonstrates a financial strategy where 0.04 expresses the metric's value today.

Company Aggregate Debts: Veracyte (VCYT) for 07/04/2022 - 10/27/2026

Analytical breakdowns and data insights for company Veracyte (VCYT)

- price and consensus price forecast:

Stock Price Veracyte Diagnostics|VCYT - Price Target Chart

- market capitalization data:

Market Capitalization Veracyte Corp|VCYT - Enterprise Value

- book capitalization data:

Accounting Value per Share Veracyte|VCYT - Book Capitalization|Market-to-Book Ratio veracyte.com|VCYT - Aggregate Company Assets

- debt and liquidity data:

All Debt to Shareholders' Equity Ratio Veracyte, Inc.|VCYT - Long-Term Debt to Equity Ratio|Ratio of Short-Term Indebtedness to Capital Veracyte Inc|VCYT - Company Aggregate Debts|Debts to Book Capitalization Veracyte Corp

General company analysis:Veracyte Diagnostics VCYT

This indicator compares total borrowings against the market capitalization of Veracyte, Inc. (VCYT), determining the degree of financial leverage relative to equity value. Stable cash flow from molecular diagnostics mitigates debt service risks; therefore, the debt chronology allows for an assessment of how effectively the company utilizes borrowed funds to scale the business without threatening operational stability.

Competitors of Veracyte, Inc. (VCYT)